The company, established in late 2019, aims to contribute to the demand in Arab countries for essential, commonly used vaccines, such as those for livestock foot-and mouth disease, bird flu and Newcastle disease, among others.
Free Zone Port of Sohar-Sultanate of Oman
The project will be implemented in two phases:
The Initial capital is OMR 200 thousands, and shareholders are:
The company's estimated sales at stability year (the tenth year of production) are estimated at USD 52.7 million
The market share is estimated at 12%.
- Foot Mouth Disease (FMD) vaccine
- Newcastle vaccine, bird flu vaccine, and others
The total investment cost is estimated at USD 55.4 million, representing an investment cost of USD 17.36 million at phase I and USD 38.04 million at phase II in addition to initial working capital estimated at USD 2.55 million.
- Phase I: 50% equity and 50% loans
- Phase II: 32% equity, 64% loans, and 4% internal finance